Edition:
United Kingdom

Apellis Pharmaceuticals Inc (APLS.OQ)

APLS.OQ on NASDAQ Stock Exchange Global Select Market

23.87USD
26 Apr 2018
Change (% chg)

$1.52 (+6.80%)
Prev Close
$22.35
Open
$22.51
Day's High
$24.31
Day's Low
$22.51
Volume
62,984
Avg. Vol
65,466
52-wk High
$31.69
52-wk Low
$12.51

Select another date:

Thu, Feb 22 2018

BRIEF-Apellis Pharmaceuticals Announces 18-Month Results Of Phase 2 Study Of APL-2 In Geographic Atrophy

* APELLIS PHARMACEUTICALS ANNOUNCES 18-MONTH RESULTS OF PHASE 2 STUDY (FILLY) OF APL-2 IN GEOGRAPHIC ATROPHY Source text for Eikon: Further company coverage:

BRIEF-Apellis Finalizes Late Stage Trial Plans For Eye Disease Treatment

* APELLIS FINALIZES PHASE 3 CLINICAL TRIAL PLANS FOR GEOGRAPHIC ATROPHY TREATMENT WITH APL-2

BRIEF-Apellis Pharmaceuticals Appoints Timothy Sullivan as CFO

* APELLIS PHARMACEUTICALS EXPANDS MANAGEMENT TEAM, APPOINTS TIMOTHY SULLIVAN CHIEF FINANCIAL OFFICER Source text for Eikon: Further company coverage:

BRIEF-Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc

* Cormorant Asset Management LLC reports 7.05 percent passive stake in Apellis Pharmaceuticals Inc ‍​as of November 13 - SEC filing Source text (http://bit.ly/2jcJaxu) Further company coverage: (Bangalore.newsroom@thomsonreuters.com)

Select another date: